Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF signaling and targeted therapies in melanoma.

Hematology/oncology clinics of North America - 1 Jun 2009

Dhomen Nathalie, Marais Richard

Abstract excerpt

The RAS/RAF/MEK/ERK signaling pathway has emerged as a major player in the induction and maintenance of melanoma, particularly the protein kinase BRAF, mutated in approximately 44% of melanoma cases. The availability of new drugs affecting the components of this pathway and pathways that may cooperate with MAPK signaling, means that targeted therapies are fast becoming a real option in the clinical management of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Drug Delivery Systems
Share to Drugs, Investigational

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Mitogen-Activated Protein Kinase Kinases

Share to Niacinamide

Share to Phenylurea Compounds

Share to Sorafenib

Source

Identifiers

PMID: 19464601
DOI: 10.1016/j.hoc.2009.04.001

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF signaling and targeted therapies in melanoma.PMID 19464601Read ↗

BRAF Inhibitors and MelanomaSemantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Semantic proximity Read ↗

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read ↗

Emerging targeted therapies for melanoma.Semantic proximity Read ↗

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.Semantic proximity Read ↗

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Semantic proximity Read ↗

BRAF as a potential therapeutic target in melanoma and other malignancies.Semantic proximity Read ↗

Therapeutic targets in melanoma: map kinase pathway.Semantic proximity Read ↗

BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.Semantic proximity Read ↗

Integrating BRAF/MEK inhibitors into combination therapy for melanomaSemantic proximity Read ↗

BRAF targeted therapy changes the treatment paradigm in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.